Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine

Ann Hematol. 2022 May;101(5):1089-1096. doi: 10.1007/s00277-022-04800-3. Epub 2022 Feb 26.

Abstract

Hairy cell leukemia (HCL) is a rare hematologic disorder characterized by pancytopenia and splenomegaly for which a single course of cladribine is highly effective in inducing complete remissions. However, there is limited real-world data on outcomes and complications among geriatric patients with HCL treated with cladribine. We conducted a retrospective review of all patients 70 years or older within the Scripps Clinic HCL Database at the time of first treatment with cladribine. Of the 45 patients meeting inclusion criteria, 32 (71%) achieved CR and 4 (9%) achieved PR. Of the 9 remaining patients, 7 achieved normalization of peripheral blood counts after a single course of cladribine (complete hematologic response, CHR) and 2 had no response. The median duration of response for all responders was 119 months. Nine (20%) patients relapsed with a median time to first relapse of 28 months. Ten patients subsequently developed 12 primary malignancies with an excess frequency (observed-to-expected ratio) of 0.85 (95% confidence interval, 0.48-1.49). Median overall survival for the entire cohort was 166 months from time of HCL diagnosis and 119 months from time of first cladribine administration. Forty patient deaths were observed; the standardized mortality ratio (observed-to-expected ratio) was 1.42 (95% confidence interval, 1.03-1.96), representing a statistically significant increase in the risk of death (P = .03). This study supports the high rate of complete and durable responses following a single course of cladribine in geriatric patients.

Keywords: Cladribine; Durable responses; Geriatric; Hairy cell leukemia.

MeSH terms

  • Aged
  • Antineoplastic Agents* / therapeutic use
  • Cladribine / therapeutic use
  • Humans
  • Leukemia, Hairy Cell* / pathology
  • Remission Induction
  • Retrospective Studies

Substances

  • Antineoplastic Agents
  • Cladribine